Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Sena Kim, Sora Lim, Boram Kim, Julie Ritchey, Kiran Vij, Julie Prior, Lynne Marsala, Alyssa Stoner, Feng Gao, Samuel Achilefu, Matthew L. Cooper, John F. DiPersio, Jaebok Choi

Blood (2023) 141 (8): 945–950.

https://doi.org/10.1182/blood.2021012687

Published: 2023

Includes: Supplemental data

Journal Articles

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

Kidist Ashami, BA, Kiran R. Vij, MD, Julie Ritchey, Srikanth Santhanam, PhD, Karl W. Staser, MD PhD, Sora Lim, Sena Kim, Matthew L. Cooper, PhD, Feng Gao, PhD, Matthew Ciorba, John F. DiPersio, MD PhD, Jaebok Choi, PhD

Blood (2018) 132 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2018-99-119470

Published: 2018

Journal Articles

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

Matt L Cooper, PhD, Karl W. Staser, MD PhD, Julie Ritchey, Jessica Niswonger, Byung Ha Lee, PhD, Jaehan Park, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2199.

https://doi.org/10.1182/blood-2018-99-117265

Published: 2018

Journal Articles

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Linda G Eissenberg, PhD, Julie Ritchey, Michael P. Rettig, PhD, Judith A. Fox, PhD, Jeanmarie Guenot, PhD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2018-99-118573

Published: 2018

Journal Articles

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Elisa De Togni, BA, Miriam Y Kim, MD, Matt L Cooper, PhD, Julie Ritchey, Julie O'Neal, PhD, Jessica Niswonger, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 2205.

https://doi.org/10.1182/blood-2018-99-113438

Published: 2018

Journal Articles

Generation and Characterization of Murine Allogeneic T Cell Resistant APL Cells

Ezhilarasi Chendamarai, PhD, Michael P Rettig, PhD, Gue Su Chang, PhD, Allegra A Petti, PhD, Christopher A Miller, PhD, Julie Ritchey, Lukas D Wartman, MD, Timothy J Ley, MD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 3170.

https://doi.org/10.1182/blood.V130.Suppl_1.3170.3170

Published: 2017

Journal Articles

Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist

Moses O. Evbuomwan, Richard F Heier, BS, Darja Karpova, PhD, Stephanie Christ, MS, Ezhilarasi Chendamarai, PhD, Michael P Rettig, PhD, Linda G Eissenberg, PhD, Stacy D Arnett, PhD, Julie Ritchey, Marvin J Meyers, PhD, Peter G Ruminski, BS, David W Griggs, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2017) 130 (Supplement 1): 3197.

https://doi.org/10.1182/blood.V130.Suppl_1.3197.3197

Published: 2017

Journal Articles

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Blood (2017) 130 (Supplement 1): 844.

https://doi.org/10.1182/blood.V130.Suppl_1.844.844

Published: 2017

Journal Articles

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Chantiya Chanswangphuwana, MD, Michael P. Rettig, PhD, Walter Akers, Deep Hathi, Matthew Holt, Julie O'Neal, PhD, Julie Ritchey, Danny Kohnen, Justin A King, Michael H. Tomasson, MD, Ravi Vij, MD, Monica Shokeen, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2056.

https://doi.org/10.1182/blood.V128.22.2056.2056

Published: 2016

Journal Articles

A CD47xCD19 Bispecific Antibody That Remodels the Tumor Microenvironment for Improved Killing and Provokes a Memory Immune Response to Cancer B Cells

Walter G. Ferlin, PhD, Xavier Chauchet, PhD PharmD, Vanessa Buatois, PhD, Susana Salgado-Pires, PhD, Limin Shang, PhD, Elie Dheilly, MSc, Krzysztof Masternak, PhD, Zoë Johnson, PhD, John F DiPersio, MD PhD, Julie Ritchey, Linda Eissenberg, PhD, Marie H. Kosco-Vilbois, PhD, Nicolas Fischer, PhD

Blood (2016) 128 (22): 44.

https://doi.org/10.1182/blood.V128.22.44.44

Published: 2016

Journal Articles

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Darja Karpova, PhD, Michael P. Rettig, PhD, Linda Eissenberg, PhD, Julie Ritchey, Matthew Holt, Richard Heier, Stacy Arnett, PhD, Marvin Meyers, PhD, David W. Griggs, PhD, Peter Ruminski, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 659.

https://doi.org/10.1182/blood.V128.22.659.659

Published: 2016

Journal Articles

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Darja Karpova, PhD, Julie Ritchey, Matthew Holt, Darlene Monlish, PhD, Laura G. Schuettpelz, MD PhD, Wei Yang, Jean-Pierre Levesque, PhD, Allison Robyn Pettit, PhD BSc, Michael P. Rettig, PhD, Halvard Bonig, MD MA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2648.

https://doi.org/10.1182/blood.V128.22.2648.2648

Published: 2016

Journal Articles

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Bader Alahmari, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, Bing Wang, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3344.

https://doi.org/10.1182/blood.V128.22.3344.3344

Published: 2016

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Armin Ghobadi, MD, Michael P. Rettig, PhD, Matthew Holt, Julie Ritchey, Linda Eissenberg, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 513.

https://doi.org/10.1182/blood.V126.23.513.513

Published: 2015

Journal Articles

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

Bader Alahmari, MBBS, Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 4283.

https://doi.org/10.1182/blood.V126.23.4283.4283

Published: 2015

Journal Articles

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Matthew L Cooper, PhD, Jaebok Choi, PhD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3828.

https://doi.org/10.1182/blood.V124.21.3828.3828

Published: 2014

Journal Articles

Targeting VLA-4 to Reduce GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Bader Alahmari, MD, Julie Ritchey, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 3829.

https://doi.org/10.1182/blood.V124.21.3829.3829

Published: 2014

Journal Articles

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Jaebok Choi, PhD, Matthew L Cooper, PhD, Julie Ritchey, Lynne Collins, Julie Prior, David Piwnica-Worms, MD, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 4464.

https://doi.org/10.1182/blood.V122.21.4464.4464

Published: 2013

NARROW

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

S100A9 upregulated by IFNGR signaling blockade functions as a novel GVHD suppressor without compromising GVL in mice

Baricitinib Prevents and Treats GvHD through Both Immune Modulation and Enhancement of Tissue Repair

A Long-Acting Pharmacological Grade Interleukin-7 Molecule Logarithmically Accelerates Ucart Proliferation, Differentiation, and Tumor Killing

AMV564, a Bivalent Bispecific (2×2) CD33/CD3 T-Cell Engager, Is Active and Improves Survival in a Mouse Model of Acute Myeloid Leukemia

Chimeric Antigen Receptor T Cells Specific for CLL-1 for Treatment of Acute Myeloid Leukemia

Generation and Characterization of Murine Allogeneic T Cell Resistant APL Cells

Generation and Characterization of Novel VLA-4 Inhibitors for Stem Cell Mobilization in Combination with a CXCR2 Agonist

An Off-the-Shelf™ Fratricide-Resistant CAR-T for the Treatment of T Cell Hematologic Malignancies

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

A CD47xCD19 Bispecific Antibody That Remodels the Tumor Microenvironment for Improved Killing and Provokes a Memory Immune Response to Cancer B Cells

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Selective Inhibition of α4β1 Integrin (VLA-4) Mitigates GvHD

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Targeting Alpha 4 Integrin (CD49d) to Reduce GvHD

Dysregulated Overexpression of S100A8 and S100A9 Calgranulin Family Proteins in IFNγR-/- Allogeneic T Cells Is Associated with Reduced Graft Versus Host Disease in Vivo

Targeting VLA-4 to Reduce GvHD

IFNγR Signaling As a Therapeutic Target To Prevent GvHD While Preserving Gvl

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only